Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial

Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial

Abstract Background Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitor (Empagliflozin) is an effective drug in controlling blood glucose through predominantly glycosuria. Glycosuria increases the risk of genitourinary infections in diabetes. This study was aimed to establish the safety and efficacy o...

Full description

Bibliographic Details
Main Authors: Azizul Hasan Aamir, Umar Yousaf Raja, Faisal Masood Qureshi, Ali Asghar, Saeed Ahmed Mahar, Ibrar Ahmed, Tahir Ghaffar, Jamal Zafar, Mohammad Imtiaz Hasan, Amna Riaz, Syed Abbas Raza, Irshad Ahmed Khosa, Jahanzeb Khan, Jaffer Bin Baqar
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Endocrine Disorders
Subjects:
SLT2 inhibitors
HbA1c
Safety
Efficacy
Pakistani
Muslims
Online Access:https://doi.org/10.1186/s12902-022-01213-1

Internet

https://doi.org/10.1186/s12902-022-01213-1

Similar Items